Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety.

Conclusions: The DCV+ASV therapy resulted in a high SVR12 and improved liver fibrosis; the treatment was well tolerated in patients with genotype 1b HCV infections. PMID: 29409309 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29409309?dopt=Abstract

Source: Gut and Liver - February 9, 2018 Category: Gastroenterology Tags: Gut Liver Source Type: research